TCR2 Therapeutics

General Information


We are an innovative immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. Our proprietary TCR Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex, which we believe is essential for T cell therapies to be effective in patients with solid tumors.

Employees: 45
Founded: 2015
Contact Information
Address 100 Binney Street, Suite 710, Cambridge, MA 02142, US
Phone Number (617) 949-5200
Web Address
View Prospectus: TCR2 Therapeutics
Financial Information
Market Cap $347.8mil
Revenues $0 mil (last 12 months)
Net Income $-20.6 mil (last 12 months)
IPO Profile
Symbol TCRR
Exchange NASDAQ
Shares (millions): 5.0
Price range $15.00 - $15.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Jefferies/ Leerink Partners/ BMO Capital Markets
CO-Managers Wedbush PacGrow/ China Renaissance
Expected To Trade: 2/14/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change